Psychedelics and the science of self-experience

Nour, M. M., & Carhart-Harris, R. L. | The British Journal of Psychiatry | 1 March 2017

Synthesis of New Harmine Isoxazoles and Evaluation of their Potential Anti-Alzheimer, Anti-inflammatory, and Anticancer Activities

Filali, I., Romdhane, A., Znati, M., B Jannet, H., & Bouajila, J. | Medicinal Chemistry | 1 March 2017

Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review

Hamid, H. A., Ramli, A. N., & Yusoff, M. M. | Frontiers in Pharmacology | 28 February 2017

Effects of Hallucinogens on Neuronal Activity

Lladó-Pelfort, L., Celada, P., Riga, M. S., Troyano-Rodríguez, E., Santana, N., & Artigas, F. | Current Topics in Behavioural Neuroscience | 26 February 2017

22-azidosalvinorin A exhibits antidepressant-like effect in mice

Fajemiroye, J. O., Prabhakar, P. R., da Cunha, C. L., Costa, E. A., & Zjawiony, J. K. | European Journal of Pharmacology | 17 February 2017

Altered Insula Connectivity Under MDMA

Walpola, I. C., Nest, T., Roseman, L., Erritzoe, D., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 14 February 2017

Short term changes in the proteome of human cerebral organoids induced by 5-methoxy-N,N-dimethyltryptamine

Dakic, V., Nascimento, J. M., Sartore, R. C., de Moraes Maciel, R., de Araujo, D. B., Ribeiro, S., ... & Rehen, S. K. | bioRxiv | 13 February 2017

Effect of a Hallucinogenic Serotonin 5-HT2A Receptor Agonist on Visually-Guided, Hippocampal-Dependent Spatial Cognition in C57BL/6J Mice

Zhang, G., Cinalli, D., & Stackman, R. W. | Hippocampus | 1 February 2017

Prophylactic Ketamine Attenuates Learned Fear

McGowan, J. C., LaGamma, C. T., Lim, S. C., Tsitsiklis, M., Neria, Y., Brachman, R. A., & Denny, C. A. | Neuropsychopharmacology | 27 January 2017

The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation

Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., ... & Vollenweider, F. X. | Current Biology | 26 January 2017

Crystal Structure of an LSD-Bound Human Serotonin Receptor

Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., ... & Shoichet, B. K. | Cell | 26 January 2017

The fibrinolytic system: A new target for treatment of depression with psychedelics

Idell, R. D., Florova, G., Komissarov, A. A., Shetty, S., Girard, R. B. S., & Idell, S. | Medical Hypotheses | 23 January 2017

Pharmacology and Toxicology of N-Benzylphenethylamine (“NBOMe”) Hallucinogens

Halberstadt, A. L. | Current Topics in Behavioral Neurosciences | 18 January 2017

Harmine stimulates proliferation of human neural progenitors

Dakic, V., de Moraes Maciel, R., Drummond, H., Nascimento, J. M., Trindade, P., & Rehen, S. K. | PeerJ | 6 December 2016

Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT

Ma, K. H., Liu, T. T., Weng, S. J., Chen, C. F. F., Huang, Y. S., Chueh, S. H., ... & Huang, W. S. | Scientific Reports | 1 December 2016

Ecstasy research: will increasing observational data aid our understanding of MDMA?

Amoroso, T. | The Lancet Psychiatry | 1 December 2016

d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology

De Gregorio, D., Comai, S., Posa, L., & Gobbi, G. | International Journal of Molecular Sciences | 23 November 2016

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant

Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. | Neuroscience Bulletin | 22 November 2016

Biosynthesis of the psychotropic plant diterpene salvinorin A: Discovery and characterization of the Salvia divinorum clerodienyl diphosphate synthase

Pelot, K. A., Mitchell, R., Kwon, M., Hagelthorn, D. M., Wardman, J. F., Chiang, A., ... & Zerbe, P. | The Plant Journal | 19 November 2016

The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens

Canal, C. E., & Murnane, K. S. | Journal of Psychopharmacology | 15 November 2016

MOLECULAR DOCKING STUDIES ON THE THERAPEUTIC TARGETS OF ALZHEIMER DISEASE (ACHE AND BCHE) USING NATURAL BIOACTIVE ALKALOIDS

Jyothi, P., & Yellamma, K. | International Journal of Pharmacy and Pharmaceutical Sciences | 1 November 2016

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging

dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. | Neuroscience & Biobehavioral Reviews | 31 October 2016

The Endogenous Hallucinogen and Trace Amine N,N-Dimethyltryptamine (DMT) Displays Potent Protective Effects against Hypoxia via Sigma-1 Receptor Activation in Human Primary iPSC-Derived Cortical Neurons and Microglia-Like Immune Cells

Szabo, A., Kovacs, A., Riba, J., Djurovic, S., Rajnavolgyi, E., & Frecska, E. | Frontiers in Neuroscience | 14 September 2016

Ketamine Treatment and Global Brain Connectivity in Major Depression

Abdallah, C. G., Averill, L. A., Collins, K. A., Geha, P., Schwartz, J., Averill, C., ... & Iosifescu, D. V. | Neuropsychopharmacology | 8 September 2016

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies

Vegting, Y., Reneman, L., & Booij, J. | Psychopharmacology | 28 August 2016

The antidepressant effect of ketamine: Mediated by AMPA receptors?

Inta, D., Sprengel, R., Borgwardt, S., Lang, U. E., & Gass, P. | European Neuropsychopharmacology | 20 August 2016

The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors

De Gregorio, D., Posa, L., Ochoa-Sanchez, R., McLaughlin, R., Maione, S., Comai, S., & Gobbi, G. | Pharmacological Research | 17 August 2016

Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study

Xu, X. | Doctoral dissertation, University of Pittsburgh | 8 August 2016

Neurovascular Plasticity of the Hippocampus One Week after a Single Dose of Ketamine in Genetic Rat Model of Depression

Ardalan, M., Wegener, G., Polsinelli, B., Madsen, T. M., & Nyengaard, J. R. | Hippocampus | 21 July 2016

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience

Gallimore, A. R. and Strassman, R. | Frontiers in Pharmacology | 30 June 2016

Ketamine abuse potential and use disorder

Liu, Y., Lin, D., Wu, B., & Zhou, W. | Brain research bulletin | 31 May 2016

Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors

Ponzoni, L., Daniela, B., & Sala, M. | Psychopharmacology | 16 June 2016

Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2’S,4’S)-lysergic acid 2,4-dimethylazetidide (LSZ)

Brandt, S. D., Kavanagh, P. V., Westphal, F., Elliott, S. P., Wallach, J., Colestock, T., ... & Halberstadt, A. L. | Drug testing and analysis | 6 June 2016

Serotonin antagonists fail to alter MDMA self-administration in rats

Schenk, S., Foote, J., Aronsen, D., Bukholt, N., Highgate, Q., Van de Wetering, R., & Webster, J. | Pharmacology Biochemistry and Behavior | 2 June 2016

Potential involvement of serotonergic signaling in ketamine’s antidepressant actions: A critical review

du Jardin, K. G., Müller, H. K., Elfving, B., Dale, E., Wegener, G., & Sanchez, C. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2 June 2016

Ibogaine and addiction in the animal model, a systematic review and meta-analysis

Belgers, M., Leenaars, M., Homberg, J. R., Ritskes-Hoitinga, M., Schellekens, A. F. A., & Hooijmans, C. R. | Translational psychiatry | 31 May 2016

Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans

Nunes, A. A., dos Santos, R. G., Osório, F. L., Sanches, R. F., Crippa, J. A. S., & Hallak, J. E. | Journal of psychoactive drugs | 26 May 2016

Human Pharmacology of Mephedrone in Comparison to MDMA

Papaseit, E., Pérez-Mañá, C., Mateus, J. A., Pujadas, M., Fonseca, F., Torrens, M., ... & Farré, M. | Neuropsychopharmacology | 20 May 2016

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens

Rickly, A., Moning, O., Hoener, M., Liechti, M. | European Neuropsychopharmacology | 20 May 2016

Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Taylor, D. | The Lancet Psychiatry | 17 May 2016

Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression

Zhong, X., He, H., Zhang, C., Wang, Z., Jiang, M., Li, Q., ... & Huang, X. | Journal of Affective Disorders | 12 May 2016

Glutamate and GABA Systems in the Pathophysiology of Major Depression and Antidepressant Response to Ketamine

Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A., & Zarate, C. A. | Biological Psychiatry | 12 May 2016

LSD-induced entropic brain activity predicts subsequent personality change

Lebedev, A.V., Kaelen, M., Lövdén, M., Nilsson, J. Feilding, A., Nutt, D. J., Carhart-Harris, R. L. | Hum Brain Mapp | 6 May 2016

Depression: Ketamine steps out of the darkness

Malinow, R. | Nature | 4 May 2016

Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue—Behavioural, pharmacokinetic and metabolic studies in the Wistar rat

Horsley, R. R., Lhotkova, E., Hajkova, K., Jurasek, B., Kuchar, M., & Palenicek, T. | Brain Research Bulletin | 4 May 2016

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., ... & Dossou, K. S. | Nature | 4 May 2016

LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion

Roseman, L., Sereno, M. I., Leech, R., Kaelen, M., Orban, C., McGonigle, J., ... & Carhart‐Harris, R. L. | Human Brain Mapping | 29 April 2016

Neuropharmacology of N,N-Dimethyltryptamine

Carbonaro, T. M., & Gatch, M. B. | Brain Research Bulletin | 25 April 2016

Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial

Dakwar, E., Hart, C. L., Levin, F. R., Nunes, E. V., & Foltin, R. W. | Molecular Psychiatry | 19 April 2016

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing

Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., ... & Vollenweider, F. X. | Proceedings of the National Academy of Sciences | 18 April 2016

LSD modulates music-induced imagery via changes in parahippocampal connectivity

Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orban, C., Lorenz, R., ... & Wall, M. B. | European Neuropsychopharmacology | 12 April 2016

Harmine stimulates neurogenesis of human neural cells in vitro

Dakic, V., de Moraes Maciel, R., Drummond, H., Nascimento, J. M., Trindade, P., & Rehen, S. K. | PeerJ Preprints | 14 April 2016

Neural correlates of the LSD experience revealed by multimodal neuroimaging

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., ... & Leech, R. | Proceedings of the National Academy of Sciences | 11 April 2016

Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution

Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., ... & Bullmore, E. | Current Biology | 11 April 2016

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents

Mash, D. C., Ameer, B., Prou, D., Howes, J. F., & Maillet, E. L. | Journal of psychopharmacology (Oxford, England) | 4 April 2016

Dimethyltryptamine (DMT): a biochemical Swiss Army knife in neuroinflammation and neuroprotection?

Szabo, A., & Frecska, E. | Neural Regeneration Research | 1 April 2016

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M., Rodríguez-Pujadas, A., Antonijoan, R. M., Romero, S., ... & Feilding, A. | European Neuropsychopharmacology | 25 March 2016

Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide

Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. | Journal of psychopharmacology | 1 April 2016

Meta-analysis of executive functioning in ecstasy/polydrug users

Roberts, C. A., Jones, A., & Montgomery, C. | Psychological medicine | 11 March 2016

Ayahuasca: pharmacology, neuroscience and therapeutic potential

Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., ... & Riba, J. | Brain Research Bulletin | 11 March 2016

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Johnson, M. W., MacLean, K. A., Caspers, M. J., Prisinzano, T. E., & Griffiths, R. R. | Journal of psychopharmacology (Oxford, England) | 15 February 2016

Naltrexone but not ketanserin antagonizes the subjective, cardiovascular and neuroendocrine effects of salvinorin-A in humans

Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., ... & Barker, S. | International Journal of Neuropsychopharmacology | 12 Februari 2016

Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms

Jiang, X. L., Shen, H. W., & Yu, A. M. | Pharmacological Reports | 5 Februari 2016

Psychedelics

Nichols, D. E. | Pharmacological reviews | 3 February 2016

The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study

Li, C. T., Chen, M. H., Lin, W. C., Hong, C. J., Yang, B. H., Liu, R. S., ... & Su, T. P. | Human Brain Mapping | 29 January 2016

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

Pokorny, T., Preller, K. H., Kraehenmann, R., & Vollenweider, F. X. | European Neuropsychopharmacology | 22 January 2016

Oxytocin receptor gene variation predicts subjective responses to MDMA

Bershad, A. K., Weafer, J. J., Kirkpatrick, M. G., Wardle, M. C., Miller, M. A., & de Wit, H. | Social neuroscience | 20 January 2016

Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-NN-dimethyltryptamine

Halberstadt, A. L. | Pharmacology Biochemistry and Behavior | 15 January 2016

Genotoxic evaluations in Wistar rats of the hallucinogenic plant extract ayahuasca

Pic-Taylor, A., Junior, W. M., Souza-Filho, J., Grisolia, C. K., & Caldas, E. D. | International Journal of Phytomedicine | 1 January 2016

Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent

Frau, L., Costa, G., Porceddu, P. F., Khairnar, A., Castelli, M. P., Ennas, M. G., ... & Morelli, M. | Journal of neurochemistry | 1 January 2016

Effects of Long-Term Ayahuasca Administration on Memory and Anxiety in Rats

Favaro, V. M., Yonamine, M., Soares, J. C. K., & Oliveira, M. G. M. | PloS one | 30 December 2015

Neuroimaging in moderate MDMA use: A systematic review

Mueller, F., Lenz, C., Steiner, M., Dolder, P. C., Walter, M., Lang, U. E., ... & Borgwardt, S. | Neuroscience & Biobehavioral Reviews | 30 December 2015

Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class

Dinger, J., Woods, C., Brandt, S. D., Meyer, M. R., & Maurer, H. H. | Toxicology Letters | 17 November 2015

Binge Ethanol and MDMA Combination Exacerbates Toxic Cardiac Effects by Inducing Cellular Stress

Navarro-Zaragoza, J., Ros-Simó, C., Milanés, M. V., Valverde, O., & Laorden, M. L. | PloS one | 28 October 2015

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT1A and 5-HT2A receptors.

Riga, M. S., Bortolozzi, A., Campa, L., Artigas, F., & Celada, P. | Neuropharmacology | 20 October 2015

The Ups and Downs of 3,4-Methylenedioxymethamphetamine: Linking Subjective Effects to Spontaneous Brain Function

de Wit, H., Gorka, S. M., & Phan, K. L. | Biological psychiatry | 15 October 2015

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity

Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., ... & Tanner, M. | Biological psychiatry. | 15 October 2015

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Tylš, F., Páleníček, T., Kadeřábek, L., Lipski, M., Kubešová, A., & Horáček, J. | Behavioural pharmacology | 12 October 2015

Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)

Brandt, S. D., Kavanagh, P. V., Westphal, F., Stratford, A., Elliott, S. P., Hoang, K., ... & Halberstadt, A. L. | Drug Testing and Analysis | 12 October 2015

Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson’s Disease?

Djamshidian, A., Bernschneider‐Reif, S., Poewe, W., & Lees, A. J. | Movement Disorders Clinical Practice | 6 October 2015

Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders

Costi, S., Van Dam, N. T., & Murrough, J. W. | Current Behavioral Neuroscience Reports | 01 October 2015

Acute Biphasic Effects of Ayahuasca

Schenberg E.E., Alexandre J.F.M., Filev R., Cravo A.M., Sato J.R., Muthukumaraswamy S.D., et al. | PLoS ONE | 30 September 2015

Ketamine for depression: evidence, challenges and promise

Zarate, C. A., & Niciu, M. J. | World Psychiatry | 25 September 2015

3,4-Methylenedioxymethamphetamine facilitates fear extinction learning

Young, M. B., Andero, R., Ressler, K. J., & Howell, L. L. | Translational Psychiatry | 15 September 2015

Salvinorin A, a kappa-opioid receptor (KOP-r) agonist hallucinogen: Pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders

Butelman, E., & Kreek, M. J. | Frontiers in Pharmacology | 08 Sep 2015

Harmine blocks herpes simplex virus infection through downregulating cellular NF-κB and MAPK pathways induced by oxidative stress

Chen, D., Su, A., Fu, Y., Wang, X., Lv, X., Xu, W., ... & Wu, Z. | Antiviral research | 5 September 2015

R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects

Yang, C., Shirayama, Y., Zhang, J. C., Ren, Q., Yao, W., Ma, M., ... & Hashimoto, K. | Translational psychiatry | 1 September 2015

Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert+/−) mice

Kyzar, E. J., Stewart, A. M., & Kalueff, A. V. | Behavioural brain research | 1 Sep 2015

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity

Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. | NeuroImage: Clinical | 22 Aug 2015

Noribogaine is a G-Protein Biased κ-Opioid Receptor Agonist

Maillet, E. L., Milon, N., Heghinian, M. D., Fishback, J., Schürer, S. C., Garamszegi, N., & Mash, D. C. | Neuropharmacology | 21 Aug 2015

5-HT2A and mGlu2/3 receptor interactions: on their relevance to cognitive function and psychosis

Wischhof, L., & Koch, M. | Behavioural pharmacology | 19 Aug 2015

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

Kometer, M., Pokorny, T., Seifritz, E., & Vollenweider, F. X. | Psychopharmacology | 01 Aug 2015

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches

Al Jurdi, R. K., Swann, A., & Mathew, S. J. | Current psychiatry reports | 1 August 2015

5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study

Wright, N. E., Strong, J. A., Gilbart, E. R., Shollenbarger, S. G., & Lisdahl, K. M. | PloS one | 31 July 2015

Developmental outcomes of 3,4-methylenedioxymethamphetamine (ecstasy)-exposed infants in the UK

Singer, L. T., Moore, D. G., Min, M. O., Goodwin, J., Turner, J. J., Fulton, S., & Parrott, A. C. | Human Psychopharmacology: Clinical and Experimental | 28 July 2015

Antidepressant mechanism of ketamine: perspective from preclinical studies

Scheuing, L., Chiu, C. T., Liao, H. M., & Chuang, D. M. | Frontiers in Neuroscience | 21 July 2015

Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats.

Grimm, O., Gass, N., Weber-Fahr, W., Sartorius, A., Schenker, E., Spedding, M., ... & Meyer-Lindenberg, A. | Psychopharmacology | 18 July 2015

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain.

Spain, A., Howarth, C., Khrapitchev, A., Sharp, T., Sibson, N. R., & Martin, C. | Neuropharmacology | 17 July 2015

Ketamine induces anxiolytic effects in adult zebrafish: A multivariate statistics approach.

De Campos, E. G., Bruni, A. T., & De Martinis, B. S. | Behavioural Brain Research | 14 July 2015

Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities

Szabo, A. | Frontiers in Immunology | 14 July 2015

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder

Papakostas, G. I., & Ionescu, D. F. | Molecular psychiatry | 7 July 2015

Perceptual distortions and delusional thinking following ketamine administration are related to increased pharmacological MRI signal changes in the parietal lobe

Stone, J., Kotoula, V., Dietrich, C., De Simoni, S., Krystal, J. H., & Mehta, M. A. | Journal of Psychopharmacology | 6 July 2015

Pharmacokinetics and concentration-effect relationship of oral LSD in humans

Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., & Liechti, M. E. | International Journal of Neuropsychopharmacology | 24 June 2015

Ketamine and Phencyclidine: the good, the bad and the unexpected

Lodge, D., & Mercier, M. S. | British journal of pharmacology | 15 June 2015

Restructuring consciousness -the psychedelic state in light of integrated information theory

Gallimore, A. R. | Frontiers in Human Neuroscience | 12 June 2015

Chronic MDMA induces neurochemical changes in the hippocampus of adolescent and young adult rats: Down-regulation of apoptotic markers

García-Cabrerizo, R., & García-Fuster, M. J. | Neurotoxicology | 9 June 2015

Antidepressant drug action – From rapid changes on network function to network rewiring

Rantamäki, T., & Yalcin, I. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 9 June 2015

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept

Rodriguez, C. I., Kegeles, L. S., Levinson, A., Ogden, R. T., Mao, X., Milak, M. S., ... & Simpson, H. B. | Psychiatry Research: Neuroimaging | 6 June 2015

Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans

Maqueda, A. E., Valle, M., Addy, P. H., Antonijoan, R. M., Puntes, M., Coimbra, J., ... & Riba, J. | International Journal of Neuropsychopharmacology | 5 June 2015

Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat.

Pic-Taylor, A., da Motta, L. G., de Morais, J. A., Junior, W. M., Santos, A. D. F. A., Campos, L. A., ... & Caldas, E. D. | Behavioural processes | 3 June 2015

Single-Dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression

Kantrowitz, J. T., Halberstam, B., & Gangwisch, J. | The Journal of clinical psychiatry | 1 June 2015

Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin

Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. | Human brain mapping | 22 May 2015

Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile

Joules, R., Doyle, O. M., Schwarz, A. J., O’Daly, O. G., Brammer, M., Williams, S. C., & Mehta, M. A. | Psychopharmacology | 19 May 2015

Immunomodulatory activity of ketamine in human astroglial A172 cells: Possible relevance to its rapid antidepressant activity.

Yuhas, Y., Ashkenazi, S., Berent, E., & Weizman, A. | Journal of neuroimmunology | 15 May 2015

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.

Andrade, C. | The Journal of clinical psychiatry | May 2015

MDMA for the treatment of mood disorder: all talk no substance?

Patel, R., & Titheradge, D. | Therapeutic Advances in Psychopharmacology | 1 May 2015

Ibogan, Tacaman, and Cytotoxic Bisindole Alkaloids from Tabernaemontana. Cononusine, an Iboga Alkaloid with Unusual Incorporation of a Pyrrolidone Moiety

Lim, K. H., Raja, V. J., Bradshaw, T. D., Lim, S. H., Low, Y. Y., & Kam, T. S. | Journal of natural products | 28 April 2015

Ketamine-A Narrative Review of Its Uses in Medicine

Radvansky, B. M., Puri, S., Sifonios, A. N., Eloy, J. D., & Le, V. | American Journal of Therapeutics | Apr 24 2015

Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia

Höflich, A., Hahn, A., Küblböck, M., Kranz, G. S., Vanicek, T., Windischberger, C., ... & Guertel, W. | The international journal of neuropsychopharmacology | 20 April 2015

Serotonergic psychedelics temporarily modify information transfer in humans

Alonso, J. F., Romero, S., Mañanas, M. À., & Riba, J. | International Journal of Neuropsychopharmacology | 28 March 2015

Classic hallucinogens in the treatment of addictions

Bogenschutz, M. P., & Johnson, M. W. | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 14 March 2015

Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Abdallah, C. G., Averill, L. A. and Krystal, J. H. | Annals of the New York Academy of Sciences | 27 Feb 2015

A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects

Liester, M. B. | Current Drug Abuse Reviews | 23 February 2015

What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare?

Mackenzie, R. | Current Drug Abuse Reviews | 23 February 2015

Editorial (Thematic Issue: Introduction to ‘Beneficial Effects of Psychedelics with a Special Focus on Addictions’)

Breeksema, J. J., & Kortekaas, R. | Current Drug Abuse Reviews | 23 February 2015

The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network

Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J., Hallak, J. A., ... Araujo, D. B. | PLoS One | 18 February 2015

The subjective experience of acute, experimentally-induced Salvia divinorum inebriation

Addy, P. H., Garcia-Romeu, A., Metzger, M., & Wade, J. | Journal of Psychopharmacology | 17 February 2015

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder

Murrough, J. W., Collins, K. A., Fields, J., DeWilde, K. E., Phillips, M. L., Mathew, S. J., ... & Iosifescu, D. V. | Translational psychiatry | 17 February 2015

Neural correlates of change in major depressive disorder anhedonia following open-label ketamine

Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. | Journal of Psychopharmacology | 17 February 2015

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

Majić, T., Schmidt, T. T., & Gallinat, J. | Journal of Psychopharmacology | 9 February 2015

Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes

Nikolić-Kokić, A., Oreščanin-Dušić, Z., Spasojević, I., Slavić, M., Mijušković, A., Paškulin, R., ... & Blagojević, D. P. | Journal of ethnopharmacology | 7 Februari 2015

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., & Riba, J. | Current Topics in Behavioral Neuroscience | 6 February 2015

Drug models of schizophrenia

Steeds, H., Carhart-Harris, R. L., & Stone, J. M. | Therapeutic Advances in Psychopharmacology | 5 February 2015

Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia

Xu, K., Krystal, J. H., Ning, Y., He, H., Wang, D., Ke, X., ... & Fan, N. | Journal of psychiatric research | February 2015

Antidepressant actions of ketamine: from molecular mechanisms to clinical practice

Monteggia, L. M., & Zarate, C. | Current opinion in neurobiology | 1 February 2015

Editorial (Thematic Issue: Introduction to ‘Beneficial Effects of Psychedelics with a Special Focus on Addictions’)

Kortekaas, R., & Breeksema, J. J. | Current Drug Abuse Reviews | 28 January 2015

Ayahuasca, Psychedelic Studies and Health Sciences: The Politics of Knowledge and Inquiry into an Amazonian Plant Brew

Tupper, K. W., & Labate, B. C. | Current Drug Abuse Reviews | 28 January 2015

Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca

Winkelman, M. | Current Drug Abuse Reviews | 28 January 2015

Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans

Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., ... & Riba, J. | European Neuropsychopharmacology | 16 January 2015

Making a medicine out of MDMA

Sessa, B., & Nutt, D. | The British Journal of Psychiatry | 5 January 2015

Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model.

Nau, F., Miller, J., Saravia, J., Ahlert, T., Yu, B., Happel, K. I., ... & Nichols, C. D. | American Journal of Physiology-Lung Cellular and Molecular Physiology | 1 January 2015

Ketamine interactions with biomarkers of stress: A randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men

Mahani, N. K., Niesters, M., van Osch, M. J., Oitzl, M., Veer, I., de Rooij, M., ... & Dahan, A. | NeuroImage | 29 December 2014

Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression

Drewniany, E., Han, J., Hancock, C., Jones, R. L., Lim, J., Nemat Gorgani, N., ... & Raffa, R. B. | Journal of Clinical Pharmacy and Therapeutics | 26 December 2014

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., ... & Liechti, M. E. | Biological psychiatry | 29 November 2014

A single infusion of ketamine improves depression scores in patients with anxious bipolar depression

Ionescu, D. F., Luckenbaugh, D. A., Niciu, M. J., Richards, E. M., & Zarate, C. A. | Bipolar disorders | 14 November 2014

Ketamine and other potential glutamate antidepressants

Dutta, A., McKie, S., & Deakin, J. W. | Psychiatry research | 12 November 2014

Harmine mediated neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia.

Sun, P., Zhang, S., Li, Y., & Wang, L. | Neuroscience letters | 7 November 2014

On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis

Grammenos, D., & Barker, S. A. | Journal of Neural Transmission | 2 November 2014

Single Ketamine Infusion and Neurocognitive Performance in Bipolar Depression

Permoda-Osip, A., Kisielewski, J., Bartkowska-Sniatkowska, A., & Rybakowski, J. K. | Pharmacopsychiatry | 27 October 2014

Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats

Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., ... & Taguchi, K. | Biological and Pharmaceutical Bulletin | 24 October 2014

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Sanacora, G., & Schatzberg, A. F. | Neuropsychopharmacology | 22 October 2014

Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics

Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. | Medicine | 17 October 2014

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. | Translational psychiatry | 14 October 2014

The role of ketamine in treatment-resistant depression: a systematic review

Serafini, G., H Howland, R., Rovedi, F., Girardi, P., & Amore, M. | Current neuropharmacology | 12 September 2014

Blood d-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine

Hashimoto, K. | Psychopharmacology | 5 September 2014

Ketamine safety and tolerability in clinical trials for treatment-resistant depression

Wan, L. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., ... & Murrough, J. W. | The Journal of clinical psychiatry | 2 September 2014

Entheogens, Mysticism, and Neuroscience

Cole-Turner, R. | Zygon: Journal of Religion and Science | 26 August 2014

Recent advances in the neuropsychopharmacology of serotonergic hallucinogens

Halberstadt, A. L. | Behavioural Brain Research | 15 July 2014

The role of 5-HT2A, 5-HT2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice

Carbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. | Psychopharmacology | 3 July 2014

Enhanced repertoire of brain dynamical states during the psychedelic experience

Tagliazucchi, E., Carhart-Harris, R. L., Leech, R., Nutt, D., & Chialvo, D. R. | Human Brain Mapping | 2 July 2014

(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function

Paul, R. K., Singh, N. S., Khadeer, M., Moaddel, R., Sanghvi, M., Green, C. E., ... & Wainer, I. W. | The Journal of the American Society of Anesthesiologists | 1 July 2014

Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases

Litjens, R. P., Brunt, T. M., Alderliefste, G. J., & Westerink, R. H. | European Neuropsychopharmacology | June 2014

Pharmacology of Hallucinations: Several Mechanisms for One Single Symptom?

Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. | Biomed Research International | 4 June 2014

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers

Roseman, L., Leech, R., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. | Frontiers in Human Neuroscience | 27 May 2014

The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat

Rambousek, L., Palenicek, T., Vales, K., & Stuchlik, A. | Frontiers in Behavioral Neuroscience | 16 May 2014

Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling

Buchborn, T., Schröder, H., Höllt, V., & Grecksch, G. | Journal of Psychopharmacology | 30 April 2014

Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenwieder, F. X. | Biological Psychiatry | 26 April 2014

Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles

Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. | Therapeutic Advances in Psychopharmacology | 17 March 2014

Therapeutic Effects of Ritual Ayahuasca Use in the Treatment of Substance Dependence—Qualitative Results

Loizaga-Velder, A., & Verres, R. | Journal of Psychoactive Drugs | 11 March 2014

MDMA and the “Ecstasy Paradigm”

Cole, J. C. | Journal of Psychoactive Drugs | 11 March 2014

The Potential Dangers of Using MDMA for Psychotherapy

Parrott, A. C. | Journal of Psychoactive Drugs | 11 March 2014

Therapeutic infusions of ketamine: Do the psychoactive effects matter?

Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. | Drug and alcohol dependence | 18 Feb 2014

Do the dissociative side effects of ketamine mediate its antidepressant effects?

Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., ... & Zarate, C. A. | Journal of affective disorders | 18 Feb 2014

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. | Frontiers in Human Neuroscience | 3 February 2014

The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labelling and Blood Oxygen Level-Dependent Resting-State Functional Connectivity

Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzoe, D., Wall, M. B., Ferguson, B., ... Nutt, D. J. | Biological Psychiatry | 10 January 2014

Psilocybin – Summary of knowledge and new perspectives

Tylš, F., Páleníček, T., & Horáček, J. | European Neuropsychopharmacology | 17 December 2013

Reviewing the ketamine model for schizophrenia

Frohlich, J., & van Horn, J. D. | Journal of Psychopharmacology | 20 November 2013

Serotonergic hyperactivity as a potential factor in developmental, acquired and drug-induced synesthesia

Brogaard, B. | Frontiers in Human Neuroscience | 21 October 2013

MDMA enhances emotional empathy and prosocial behavior

Hysek, C. M., Schmid, Y., Simmler, L. D., Domes, G., Heinrichs, M., Eisenegger, C., ... Liechti, M. E. | Social Cognitive & Affective Neuroscience | 4 October 2013

Broadband cortical desynchronization underlies the human psychedelic state

Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., ... & Feilding, A. | The Journal of Neuroscience | 18 September 2013

Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users.

Bouso, J. C., Fábregas, J. M., Antonijoan, R. M., Rodríguez-Fornells, A., & Riba, J. | Psychopharmacology | 21 June 2013

Effects of Schedule I drug laws on neuroscience research and treatment innovation

Nutt, D. J., King, L. A., & Nichols, D. E.| Nature Reviews Neuroscience | 12 June 2013

The Ketamine Analogue Methoxetamine and 3- and 4-Methoxy Analogues of Phencyclidine Are High Affinity and Selective Ligands for the Glutamate NMDA Receptor

Roth, B. L., Gibbons, S., Arunotayanun, W., Huang, X. P., Setola, V., Treble, R., & Iversen, L. | PLoS One | 19 March 2013

Hallucinogen persisting perception disorder: what do we know after 50 years?

Halpern, J. H., & Harrison, G. P. Jr. | Drug and Alcohol Dependence | 1 March 2013

Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin

Bogenschutz, M. P. | Current Drug Abuse Reviews | 1 March 2013

Can MDMA Play a Role in the Treatment of Substance Abuse?

Jerome, L, Schuster, S., & Yazar-Klosinski, B. B. | Current Drug Abuse Reviews | 1 March 2013

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors

Kometer, M., Schmidt, A., Bachmann, R., Studerus, E., Seifritz, E., & Vollenweider, F. X. | Biological Psychiatry | 19 December 2012

Functional Connectivity Measures After Psilocybin Inform a Novel Hypothesis of Early Psychosis

Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T. M., Stone, J. M., Evans, J., .... Nutt, D. J. | Schizophrenia Bulletin | 8 October 2012

Personality, Psychopathology, Life Attitudes and Neuropsychological Performance among Ritual Users of Ayahuasca: A Longitudinal Study

Bouso, J. C, González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., ... Riba, J. | PLoS ONE | 8 August 2012

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

Schmidt, A., Kometer, M., Bachmann, R., Seifritz, E., & Vollenweider, F.X. | Psychopharmacology | 27 July 2012

Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies

Ross, S. | Psychiatric Clinics of North America | 1 June 2012

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., ... Nutt, D. J. | Proceedings of the National Academy of Sciences of the United States of America | January 2012

Drugs as instruments: A new framework for non-addictive psychoactive drug use

Müller, C. P., & Schumann, G.| Behavioral and Brain Sciences | 10 November 2011

Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers

Quednow, B. B., Kometer, M., Geyerand, M. A., & Vollenweider, F. X. | Neuropsychopharmacology | 28 September 2011

Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion

de Aurojo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., ... Santos, A. C. | Human Brain Mapping | 16 September 2011

Bringing Ayahuasca to the Clinical Research Laboratory

Riba, J., & Barbanoj, M. J. | Journal of Psychoactive Drugs | 7 September 2011

In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin 2A Receptor Binding in MDMA and Hallucinogen Users

Erritzoe, D., Frokjaer, V. G., Holst, K. K., Christoffersen, M., Johansen, S. S., Svarer, C., ... Knudsen, G. M. | Archives of General Psychiatry | 6 June 2011

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Kometer, M., Cahn, B. R., Andel, D., Carter, O. L., & Vollenweider, F. X. | Biological Psychiatry | 1 March 2011

Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs

Halpern, J. H., Sherwood, A. R., Hudson, J. I., Gruber, S. Kozin, D., & Pope Jr., H. G. | Addiction | 15 February 2011

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., & Geyer, M.A. | Neuropharmacology | 20 January 2011

Psychobiology of Drug-Induced Religious Experience: From the Brain ‘Locus of Religion’ to Cognitive Unbinding

Nencini, P., & Grant, G. A. | Substance Use & Misuse | November 2010

Glutamatergic Model Psychoses: Prediction Error, Learning, and Inference

Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. | Neuropsychopharmacology Reviews | 22 September 2010

Abnormal visual experiences in individuals with histories of hallucinogen use: A web-based questionnaire

Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. | Drug and alcohol dependence | 21 Sep 2010

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series

Karst, M., Halpern, J. H., Bernateck, M., & Passie, T. | Cephalalgia | 26 Mar 2010

The persistence of the subjective in neuropsychopharmacology: observations of contemporary hallucinogen research

Langlitz, N. | History of Human Sciences | February 2010

How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale

Johansen, P. Ø., & Krebs, T. S.| Journal of Psychopharmacology | 9 March 2009

The Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin

Richards, W. A. | Archive for the Psychology of Religion | October 2008

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., & Griffiths, R. R. | Journal of Psychopharmacology | 1 July 2008

[Hallucinogen-induced psychological disorders]

Hermle, L., Kovar, K. A., Hewer, W., & Ruchsow, M. | Fortschritte der Neurologie-Psychiatrie | 1 June 2008

Selective 5-HT2A agonist hallucinogens: A review of pharmacological interaction and corollary perceptual effects

Kent, J. | Beta Review | 23 May 2008

Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans

Carter, O. L., Hasler, F., Pettigrew, J. D., Wallis, G. M., Liu, G. B., & Vollenweider, F. X. | Psychopharmacology | 14 September 2007

Psilocybin-induced stimulus control in the rat

Winter, J. C., Rice, K. C., Amorosi, D. J., & Rabin, R. A. | Pharmacology Biochemistry and Behavior | 22 June 2007

The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval

Vollenweider, F. X, Csomor, P. A., Knappe, B., Geyer, M. A., & Quednow, B. B. | Neuropsychopharmacology | 14 February 2007

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.

González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., ... & Gingrich, J. A. | Neuron | 1 February 2007

Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors

Carter, O. L., Burr, D. C., Pettigrew, J. D., Wallis, G. M., Hasler, F., & Vollenweider, F. X. | Journal of Cognitive neuroscience | 1 October 2005

Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion

Passie, T., Hartmann, U., Schneider, U., Emrich, H. M., & Krüger, T. H. | Medical hypotheses | 09 Nov 2004

Hallucinogens

Nichols, D. E. | Pharmacology & therapeutics | 28 January 2004

Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia

Umbricht, D., Vollenweider, F. X., Schmid, L., Gruebel, C., Skrabo, A., Huber, T., & Koller, R. | Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology | 1 Februari 2003

Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers

Riba, J., Anderer, P., Morte, A., Urbano, G., Jané, F., Saletu, B., & Barbanoj, M. J. | British journal of clinical pharmacology | 24 June 2002

No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study

Gamma, A., Buck, A., Berthold, T., & Vollenweider, F. X. | Journal of clinical psychopharmacology | 01 February 2001

Role of Serotoninergic Neurons and 5-HT Receptors in the Action of Hallucinogens

Nichols, D. E. | Serotoninergic Neurons and 5-HT Receptors in the CNS | 1 January 2000

Ketamine psychedelic therapy (KPT): a review of the results of ten years of research

Krupitsky, E. M., & Grinenko, A. Y. | Journal of psychoactive drugs | 1997

Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis

Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J. | Neuropsychopharmacology | October 1996

Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens

Nichols, D. E. | Journal of psychoactive drugs | 1 January 1986

Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca

McKenna, D. J., Towers, G. N., & Abbott, F. | Journal of ethnopharmacology | 1 April 1984